{"analyses":[{"ciLowerLimit":"0.81","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.84","estimateComment":"Based on Cox regression model with treatment as a covariate stratified by \"Age\" (\\<75 years vs \\>= 75 years) and \"ISS stage\" (I or II vs. III).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.83416","paramType":"Hazard Ratio (HR)","paramValue":"1.22","statisticalMethod":"Stratified log-rank test"}],"classes":[{"categories":[{"measurements":[{"comment":"The Median was not reached, and the Upper Limit could not be estimated due to insufficient number of events before the date of data cutoff.","groupId":"OG000","lowerLimit":"44.6","upperLimit":"NA","value":"NA"},{"comment":"The Median was not reached, and the Upper and Lower Limits could not be estimated due to insufficient number of events before the date of data cutoff.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death due to any cause. OS was calculated from the product-limit (Kaplan-Meier) method for censored data. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. This is an event-driven (events of death) outcome measure. At the time of data cut-off, there were an insufficient number of events from the censored data to be able to estimate certain parameters (e.g. medians). The database cutoff date was August 3, 2020.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.","id":"OG000","title":"Pembrolizumab + Lenalidomide + Dexamethasone"},{"description":"Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.","id":"OG001","title":"Lenolidomide + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"The analysis population included all randomized participants. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Up to approximately 55 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}